The big earners in a lucrative medical market
Tuesday 19 December 1995
According to John Hodgson, European publishing manager of Bio/technology magazine, some 26 genetically engineered pharmaceuticals have now been licensed for use around the world - 20 of which have been accepted in the UK.
Amgen, the American start-up biotechnology company, has the two top- selling genetically engineered drugs in the US. The company's Neupogen, which is used to stimulate the production of white blood cells following cancer treatment, had US sales of more than $719m last year.
In the rankings of revenue earners, Neupogen is closely followed by Epogen, an Amgen drug to stimulate the production of red blood cells. This generated US revenues of $587m last year. Such drugs are needed to treat cases of serious anaemia, which particularly afflicts people who have to undergo kidney dialysis. Amgen markets Epogen itself, but has an agreement with Ortho-Biotech to market a related red-blood cell stimulating product, known as Procrit, which is worth $500m a year in the US market.
Perhaps the most widely-used drug is human insulin for the treatment of diabetes which, produced by Genentech and marketed by Eli Lilly, has US revenues of around $560m a year. Insulin was one of the first "recombinant DNA" (genetically engineered) drugs to be approved for medicinal use, in 1982. Genentech also produces recombinant human growth hormone which is used to treat pituitary dwarfism and has annual US sales of $217m.
Life & Style blogs
What happens to your body when you give up sugar?
Why you should never make assumptions about people with autism
The big fresh food con: Alarming truth behind the chocolate muffin that won't decay
Majority of UK women don't bathe or take a shower daily
From criminal to catwalk: Convict Jeremy Meeks wins modelling contract in the most unusual fashion scouting – behind bars
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
Durham Free School: 'Creationism taught at' free school facing closure
End of the licence fee: BBC to back radical overhaul of how it is funded
Ex-head of MI6: 'We shouldn't kid ourselves that Russia is on a path to democracy'
Most people think legal tax avoidance is just as wrong as illegal tax evasion, poll suggests
Nigel Farage promises Ukip will not 'stigmatise' would-be migrants – and says he wants 'everyone to speak the same language'
- 1 Autism 'caused by genetics', study suggests
- 2 What happens to your body when you give up sugar?
- 3 Why you should never make assumptions about people with autism
- 4 Tourist films plane's descent just metres above packed Caribbean beach
- 5 Have sex with your iPad thanks to the new sex toy no-one asked for
£37500 - £45000 per annum: Recruitment Genius: Experienced Quantity Surveyor r...
£22000 - £25000 per annum: Recruitment Genius: This fast-growing company speci...
£17000 - £22000 per annum: Recruitment Genius: This is an opportunity to join ...
£25000 - £30000 per annum: Ashdown Group: IT Support Administrator - East Ridi...